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Abstract
Background and Aims: Faecal microbiota transplantation is a successful therapy for patients 
with refractory Clostridium difficile infections. It has also been suggested as a treatment option 
for inflammatory bowel disease, given the role of the intestinal microbiota in this disease. We 
assessed the impact of faecal microbiota transplantation in patients with inflammatory bowel 
disease and studied predictors of clinical (non-)response in microbial profiles of donors and 
patients.
Methods: Fourteen refractory patients (8 with ulcerative colitis and 6 with Crohn’s disease) 
underwent ileocolonoscopy with faecal microbiota transplantation through a nasojejunal (n = 9) 
or rectal (n = 5) tube. Efficacy was assessed by endoscopic healing at week 8, clinical activity 
scores and C-reactive protein measurement. Faecal microbiota was analysed by 16S rDNA 
pyrosequencing.
Results: There was no significant improvement among the 6 patients with Crohn’s disease at 
week 8 following faecal microbiota transplantation. One patient experienced temporary clinical 
remission for 6 weeks. In contrast, 2/8 patients with ulcerative colitis had endoscopic remission at 
week 8, and of the 6 remaining patients with ulcerative colitis, 1 reported temporary remission for 
6 weeks. The donor microbiota richness and the number of transferred phylotypes were associated 
with treatment success. Persistent increased C-reactive protein 2 weeks after transplantation was 
predictive of failure of response.
Conclusion: Faecal microbiota transplantation led to endoscopic and long-term (>2  years) 
remission in 2 out of 8 ulcerative colitis patients. Higher donor richness was associated with 
successful transplant. Therefore, faecal microbiota transplantation with donor prescreening could 
be a treatment option for selected refractory ulcerative colitis patients.
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1. Introduction
The microbiota plays an important role in the onset and perpetu-
ation of inflammatory bowel disease (IBD), a chronic disease with 
onset during childhood or adolescence and leading to symptoms 
of bloody diarrhoea with abdominal cramps and anorexia. The 
inflammation has a predilection for the terminal ileum in the case 
of Crohn’s disease (CD) and the colon starting from the anal mar-
gin in the case of ulcerative colitis (UC). Unresolved inflammation 
may lead to complications such as intestinal strictures or fistulas 
and abscesses. The contribution of bacteria in the disease patho-
genesis has been shown by diverse studies.1,2 Intestinal microbiota 
are essential for the development of inflammation in murine models 
of colitis and intensive genetic collaborative studies have identified 
susceptibility genes involved in the recognition of bacterial peptides 
and elimination of intracellular bacteria.1,3,4 Furthermore, the intes-
tinal mucosa in postoperative CD remains intact after diversion of 
the faecal stream, while recurrence of inflammation is observed after 
exposure of the gut to luminal contents.5
Gut commensal bacteria live in normobiosis with the host 
and have important metabolic, protective and trophic functions.6 
The overall composition of the gut microbiota and the presence 
or absence of specific species is important for homeostasis and 
tolerance of the immune system.6,7 The development of high-
throughput sequencing technologies has facilitated metagenomic 
research in determining the complexity and immense diversity 
of microbial life in various ecological niches.8–10 Metagenomic 
analysis demonstrated significant interindividual variation in gut 
microbiota composition,11–13 described as continuous gradients14 
or distinct microbiota clusters (‘enterotypes’11 or ‘co-abundance 
groups’14).
At present there is no clear evidence for a single pathogen caus-
ing IBD. On the other hand, marked alterations in microbial com-
munities are observed in IBD patients. Patients with IBD have fewer 
anti-inflammatory bacteria and/or more proinflammatory bacteria. 
Such dysbiosis has been well described in CD and more recently 
also in UC.15–22 A  reduction in Faecalibacterium prausnitzii is the 
most replicated species-specific finding so far and has been con-
firmed in faecal and mucosal samples.18,20,23–26 This species has anti-
inflammatory and immunomodulatory effects in vivo and in vitro.27 
In addition to F. prausnitzii, the adherent invasive Escherichia coli 
(AIEC) is increased in ileal mucosa of CD patients and may sustain 
inflammation.28–30
Faecal microbiota transplantation (FMT) is defined as the 
transfer of intestinal microbiota from a healthy donor and aims 
at restoring a stable microbial community in the gut of the accep-
tor. Faecal microbiota transplantation has already been shown to 
be very effective for refractory and recurrent Clostridium difficile 
infection.31 Given the importance attributed to the intestinal micro-
biota in IBD, manipulation of its composition by FMT might be a 
promising treatment if it could restore essential components of the 
microbiota, thereby reversing the inflammatory processes observed 
in this disease. Two randomized controlled trials and several case 
reports using FMT in IBD have been reported recently; most studies 
were performed in UC patients.32–42 We investigated the safety and 
efficacy of FMT in CD and UC patients refractory to conventional 
treatments in an open-label pilot study. We specifically assessed the 
influence of FMT on the diversity and composition of the microbiota 
in these patients and searched for predictors of (non-)response to 
FMT in the microbial profiles of the donors and patients.
2. Methods
2.1. Patients and donor
Between August 2011 and November 2012, 14 patients consented 
to undergo FMT (6 CD and 8 UC patients). The study protocol was 
approved by the ethics committee of University Hospitals Leuven. 
Only patients with intractable IBD could be included in this pilot 
study. Patients needed to have failed therapy with immunomodula-
tors and with anti-TNFs. Patients with UC were eligible when they 
had left-sided colitis or pancolitis and CD patients were eligible if 
they had extensive involvement of the ileum and/or colon. All but 
one CD patient had ileocolonic disease and all but one UC patient 
had extensive colitis (Table 1). Patients were not eligible to partici-
pate if they had severe comorbidities (including cardiac, pulmonary, 
renal and/or hepatic comorbidities), short bowel, a permanent ileos-
tomy or an ileoanal pouch, or if they were unable to provide written 
informed consent.
Patients were instructed to select their own donor, either 
a healthy family member (n  =  4; 3 siblings, 1 parent) or a friend 
(n  =  10; 1 partner, no other partners or household members). 
Exclusion criteria for donors were body mass index (BMI) >30, 
active smoking, known chronic diseases, antibiotic usage in the past 
6 months and detection of inflammation and/or infection in blood 
and/or faecal assessments. Donor blood was assessed for full blood 
Table 1. Baseline characteristics of the patients.
Patient Sex Age (years) Diagnosis Disease duration (years) Smoking Concomitant therapy Sex/age donor (years) Relation to donor
1 F 50 CD 27 Current None F/47 Unrelated
2 F 29 CD 10 Current None F/53 Daughter
3 M 28 CD 11 Ex Steroids M/30 Unrelated
4 F 47 CD 22 Never Steroids F/55 Unrelated
5 M 38 UC 6 Never 5-ASA M/41 Brother
6 M 41 UC 13 Current 5-ASA, steroids F/57 Brother
7 F 33 CD 16 Never None M/26 Unrelated
8 F 35 CD (UC-like) 2 Never 5-ASA F/57 Unrelated
9 M 38 UC 14 Ex 5-ASA, azathioprine M/43 Unrelated
10 M 53 UC 6 Never None F/34 Unrelated
11 M 39 UC 3 Ex Infliximab M/37 Unrelated
12 F 48 UC 4 Ex None F/44 Sister
13 F 32 UC 6 Ex None F/46 Unrelated
14 M 30 UC 3 Never 5-ASA F/27 Partner
F, female; M, male; CD, Crohn’s disease; UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid.
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count and serological testing for hepatitis A, B and C, HIV-1 and 2 
and Treponema pallidum. Donor stools were specifically screened 
for enteropathogens. Bacterial culture was performed to detect the 
following enteropathogens: Salmonella spp., Shigella spp., Yersinia 
enterocolitica, Yersinia pseudotuberculosis, Campylobacter spp. and 
Aeromonas spp. Microscopic examination was performed to search 
for eggs, cysts and/or larvae of parasites and membrane enzyme-
linked immunosorbent assay (ELISA) was done to detect C. difficile 
toxins A  and B, and glutamate dehydrogenase. For the latter, the 
polymerase chain reaction (PCR) was performed in case of discord-
ance between results of toxin and glutamate assays.
After bowel preparation using a polyethylene glycol solu-
tion, patients underwent full ileocolonoscopy with calculation of 
the Crohn’s Disease Endoscopic Index of Severity (CDEIS), the 
Simplified Endoscopic Activity Score (SES-CD) and the Mayo endos-
copy subscore (for UC) at baseline and week 8 after FMT. Data on 
C-reactive protein (CRP) and clinical disease activity were collected 
using the Crohn’s Disease Activity Index (CDAI) for CD and the 
Mayo score for UC. Patients were followed up for at least 6 months.
2.2. Efficacy endpoints
The primary endpoint for efficacy was the proportion of patients 
with endoscopic healing at week 8 defined as a Mayo endoscopic 
subscore of 0 or 1 for UC and SES-CD <3 for CD. Secondary effi-
cacy endpoints included changes in CDAI and Mayo score and 
changes in CRP. Tolerability of the procedure and adverse events 
were recorded. In addition, changes in microbial composition were 
monitored before the start and during follow-up until week 8. All 
serious adverse events (SAEs), defined as adverse events resulting in 
hospitalization, were recorded.
2.3. FMT procedure
A total of 200 g of spontaneous stools from healthy donors collected 
during the 48 h before FMT (and kept at 4°C) were homogenized 
with 400 mL sterile saline and administered in two times through 
a nasojejunal tube immediately following ileocolonoscopy and via 
the same route on the next day in the first 9 patients. As patient 9 
developed an aspiration pneumonia following vomiting on the naso-
jejunal tube, the delivery method was changed thereafter for safety 
reasons to administration via a rectal tube in all remaining patients. 
The preparation of the stool mixture was not altered, however.
2.4. Microbiome analysis
For microbiome analyses, stool samples of patients were collected 
just before bowel cleansing and FMT (= baseline) and at several 
time-points after the treatment (Supplementary Table 1). Stool sam-
ples were aliquoted and stored at –80°C within 6 h after collection. 
The sample that was used to make the stool mixture was analysed 
for each donor. DNA of fresh frozen stools was isolated according to 
Godon et al.43 and subsequently sent to BGI Tech Solutions (Hong 
Kong) Co.
The V3–V5 region of the bacterial 16S rDNA was amplified, 
introducing the 454 Life Sciences primer B (forward) and A (reverse) 
adapter sequences as well as a unique 10-base multiplex identifier 
(specific for each sample) and 2-base linker sequence (both reverse) 
and processed on a 454 GS-FLX sequencer with titanium sequenc-
ing chemistry. Sequencing outputs were filtered according to quality 
(average >25) and length (minimum 400, maximum 600) using the 
software package mothur. Chimera detection was carried out using 
UCHIME against the ‘Gold’ database (http://drive5.com/uchime/
uchime_download.html). A  subset of 5000 sequences per sample 
was used for the analyses. Clustering of sequences was performed 
using UCLUST and a 97% level operational taxonomic unit (OTU) 
table was created with Perl scripts. Classification of sequences was 
performed using RDP Classifier software.
Bacterial community comparisons were performed using the 
Vegan R package. Bray–Curtis dissimilarity was analysed using con-
strained principle component analysis (capscale) and analysis of dis-
similarity using adonis in R to test differences in various groups. All 
results were corrected for multiple testing.
3. Results
3.1. Efficacy of FMT in CD and UC
Table 2 shows the overall results for clinical and endoscopic evo-
lution following FMT. None of the CD patients had endoscopic 
healing at week 8 or clinical (CDAI) or biological (CRP) response 
(Table  2, Figure  1a). One patient with UC-like CD reported tem-
poral improvement in clinical symptoms for 6  weeks (Figure  1b). 
This patient had a normal CRP at all time-points, including baseline. 
In contrast, 2 out of the 8 UC patients went into complete remis-
sion and were still in remission in October 2014 (3 and 2.5 years) 
(Figure 1c). One additional UC patient improved transiently until 
week 6.
There were no differences at baseline in age, gender, BMI, 
CRP, haematocrit, disease duration, disease activity and/or smok-
ing between patients who responded to FMT and those who did 
not respond (all differences not significant). In patients that did not 
respond to FMT, an increase in CRP within the first 2 weeks after 
FMT was observed (p = 0.0159) (Figure 2), in both non-responding 
CD and non-responding UC patients.
3.2. Safety
Five SAEs were reported in a total of 4 patients (Supplementary 
Table 2). In 4 patients, high fever developed within a few hours after 
FMT. An urgent CT scan was performed in the first 2 patients on 
the day following FMT because of an accompanying sharp increase 
in CRP. Signs of severe colitis were seen without perforation and/or 
abscess and fever disappeared spontaneously within 2 days follow-
ing FMT. In the other patients who developed fever, a conservative 
approach with clinical observation was used and the same pattern 
was observed, with disappearance of fever after <48 hours.
Table 2. IBD activity scores at baseline and at week 8.
Week 0 Week 8 p-value
Crohn’s disease n = 6 n = 6
 CDAI median (IQR) 290 (243–359) 235 (167–330) 0.24
 CRP, mg/L, median 
(IQR)
10.9 (4.9–24.7) 6.7 (4.3–16.5) 0.49
 CDEIS, median (IQR) 11.8 (9.5–17.2) 14.7 (6.7–17.4) 0.89
 SES-CD, median (IQR) 17.5 (17–19.5) 12 (8–20) 0.94
Ulcerative colitis n = 8 n = 7
 Mayo endoscopic 
subscore (IQR)
3 (2.8–3) 3 (2.5–3) 0.47
 Total Mayo score (IQR) 8.5 (7–9.5) 7 (3.5–8.5) 0.37
 CRP, mg/L, median 
(IQR)
3.4 (2.2–5.7) 10.8 (3.3–12.5) 0.06
CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; CDEIS, 
Crohn’s Disease Endoscopic Index of Severity; SES-CD, Simplified Endoscopic 
Activity Score; IQR, interquartile range.
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a) Baseline b) Baseline c) Baseline8 weeks post FMT 8 weeks post FMT 8 weeks post FMT
CD patient A
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UC patient A
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Figure 1. Endoscopic images of inflammatory bowel disease patients at baseline and 8 weeks after faecal microbiota transplantation. (a) Three representative 
Crohn’s disease patients showing lack of endoscopic improvement. (b) Representative endoscopic images of the patient with ulcerative colitis-like Crohn’s 
disease showing partial endoscopic healing. (c) Representative endoscopic images of ulcerative colitis patients showing complete endoscopic remission.
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Figure 2. C-reactive protein (CRP) values over time for responders (blue) and non-responders (red) to faecal microbiota transplantation (FMT). A significant 
difference between successful and non-successful FMT was already observed by week 2 (p = 0.0159). R, number of responders for whom the CRP value was 
available; NR, number of non-responders for whom the CRP value was available.
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One patient vomited after FMT with aspiration and bilateral 
pneumonia on chest X-ray. This patient was treated with broad-
spectrum antibiotics for 14 days and received a second FMT 8 weeks 
later upon the patient’s specific request as the UC symptoms had not 
improved, by the rectal route. He has been in remission since.
To compare the bacterial composition between patients that 
developed fever and the patients that did not, we excluded the 
patient who had pneumonia since we could not determine estab-
lish whether the FMT also contributed to his fever. When comparing 
the most abundant genera (average abundance >1%) at baseline in 
non-responding patients, a non-significant trend of lower Alistipes 
(p = 0.052) and higher Escherichia/Shigella (p = 0.051) abundance 
was found in samples of patients developing fever (n = 3) compared 
with those who did not (n = 6).
3.3. Bacterial profiling
As expected, the baseline richness, characterized as the number of 
different bacterial OTUs, was overall higher in healthy donors com-
pared with patients. For the microbial analysis, we compared the 
patients that did not respond (n = 10) with the patients that experi-
enced clinical response for 6 weeks or more (n = 4). Interestingly, sig-
nificantly higher bacterial richness was found in donors whose stools 
resulted in successful FMT (Wilcoxon test, p  = 0.012; Figure 3a). 
Although non-significant, the same trend of higher richness at base-
line was found in patients who successfully responded to the FMT 
with UC patients displaying a slightly higher richness compared 
with CD patients (Figure 3b, c). However, species richness between 
patients and their corresponding donors at baseline did not statis-
tically differ between responders versus non-responders (Wilcoxon 
test, p = 0.5697). Combined, these results indicate that the absolute 
richness of the stool sample used for FMT and not the relative rich-
ness compared with the recipient is a marker for treatment success.
After FMT, species richness increased in all patients. At week 8, 
a trend of higher bacterial richness in patients responding to FMT 
than in those that did not respond to FMT was observed (Wilcoxon 
test, p = 0.05833).
3.4. Transfer of phylotypes
To identify clinically relevant microbial signals, we focused on effec-
tively transferred phylotypes (defined as phylotypes that are higher 
in donors than in patient at baseline, that increase after transplanta-
tion in the patients and are detected with at least 1% relative abun-
dance post-transplant in patients).33
Based upon this definition, we found in total 11 phylotypes to be 
transferred in our cohort.
Patients that did not respond to FMT had a median number 
of 1.5 transferred phylotypes, which was significantly lower than 
the number in patients that responded at least temporarily to the 
FMT, who had a median of 5 transferred phylotypes (Wilcoxon test, 
p = 0.017).
In UC patients, 4 out of 5 of the transferred phylotypes were 
shared between two patients who had a successful FMT, namely 
Roseburia, Oscillibacter, unclassified Lachnospiraceae and unclas-
sified Ruminococcaceae (Figure 4) (post-FMT samples of the third 
patient were lacking). Of them, Roseburia and Oscillibacter were 
only transferred in the two successful FMT cases but not in any of 
the other patients in our cohort. Only 1 CD patient reported tem-
porary improvement of symptoms and the transfer of 4 microbial 
phylotypes – Dialister, Prevotella, unclassified Prevotellaceae and 
unclassified Clostridiales – was observed in this patient (Figure 4).
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We also assessed transfer efficiency, i.e. the percentage of donor 
phylotypes that were absent in the patient at baseline and were 
transferred from the donor to the patient. However, no statistical dif-
ference in transfer efficiency was found between responders (median 
efficiency 74%, range 50–76%) and non-responders (median effi-
ciency 63%, range 14–83%) to FMT.
4. Discussion
Manipulation of the intestinal microbiota has been acknowledged 
as a treatment for refractory C.  difficile diarrhoea following the 
excellent results of a sham-controlled study.31 Faecal microbiota 
transplantation has since been proposed for a variety of other 
inflammatory disorders associated with dysbiosis, such as metabolic 
syndrome, irritable bowel syndrome and inflammatory bowel dis-
ease.35 Several case reports or small case series have reported on the 
success rates of FMT but not all of these analysed the changes that 
occurred in the microbiota with FMT.34,36,42 Recently, two large ran-
domized control trials with FMT in UC were published.38,39 Both tri-
als were discontinued due to futility. Of note, the study of Moayyedi 
and colleagues38 nevertheless demonstrated the efficacy of FMT in 
inducing remission in active UC patients.
We studied FMT in 14 patients with therapy-refractory CD or 
UC and used 16S rDNA sequencing to investigate who could benefit 
from this therapy. We also investigated whether analysis of donor 
and recipient prior to FMT could improve success rates. A  first 
observation was that the success rate was higher in UC than in CD. 
In CD, only 1 patient (of note, a patient with UC-like CD) reported 
a transient symptomatic improvement for 6 weeks but no clinical 
or endoscopic efficacy was observed at week 8 in the CD patients. 
In UC, one patient reported transient symptom improvement for 
6  weeks and 2 patients were in prolonged remission for 2.5 and 
3 years respectively following FMT. The success rate we observed 
is similar to what was recently reported by Rossen and colleagues39 
in their randomized controlled trial.39 Furthermore, we found that 
increased CRP levels at week 2 were an early marker of failure. This 
is an important finding as it could allow early rescue therapy in those 
IBD patients that will not benefit from FMT.
Most reports of successful FMT have been reported in UC 
patients,33,34 except for a case series from China, where impres-
sive clinical improvement was shown in CD patients.42 However, 
no endoscopy data were available in that study. Suskind and col-
leagues40 also reported a highly successful FMT study in CD; 
however, they studied a cohort of tumour necrosis factor-naive 
paediatric CD patients, whose phenotype is very different from that 
of the CD patients we assessed here. Nevertheless, the reason why 
FMT would preferentially work in UC is intriguing, as dysbiosis 
has first and mainly been described in CD.15,18 An explanation may 
lie in the mucosa-adherent bacteria, which are more important in 
CD patients, as shown by the role of AIEC.28–30 Also, the transmu-
ral inflammatory character of CD may necessitate longer treatment 
cycles, although this has never been proved. Moreover, we previ-
ously showed, using laser capture microdissection and 16S rDNA 
sequencing of selected microscopic CD lesions, that there are sig-
nificant changes in the composition and location of the gut micro-
biome in CD.44 Some of the abnormal findings persisted even after 
macroscopic mucosal healing. Finally, microbiota dysbiosis in UC is 
generally milder than in CD patients, with higher microbial richness 
in UC (see also Figure 3b and c) and microbial profiles are closer to 
those of healthy individuals, thus being potentially easier to shift.15
Faecal microbiota transplantation provoked significant fever in 
4 out of 14 patients. This was also described in a case series from 
Vienna, where all 5 UC patients reported fever following FMT.33 
A  potential explanation includes a transient translocation of bac-
teria with release of proinflammatory cytokines into the systemic 
circulation. Here, we found a trend of lower Alistipes and higher 
Escherichia/Shigella abundances in baseline samples of patients that 
developed fever.
The route of administration is still a matter of debate. Whereas 
oral administration through a nasojejunal tube would avoid the need 
to perform endoscopies, we observed one aspiration pneumonia in 
a young 38-year-old patient, without comorbidities, due to vomiting 
after placement of the tube and administration of the donor stools. 
Altering the route of administration to rectal instillation did not 
appear to affect the success rate of FMT in our study – although 
statistical analyses were hampered by the small sample size – but 
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also several authors previously reported that FMT success was not 
affected by the route of administration.35,45,46 Based on these data, 
we currently recommend that nasojejunal administration of FMT 
should not be used, to avoid the risk of aspiration pneumonia as a 
complication of FMT. Moayyedi and colleagues38 used weekly reten-
tion enemas for 6 weeks with a supernatant of faecal solution as the 
active treatment, without pretreatment with bowel lavage or antibi-
otics, and demonstrated this to be an effective treatment for active 
UC. Using this gentler approach, they also induced a significant 
increase in microbiota diversity in the treatment group compared 
with the placebo group.
The most important limitation of our study remains its small 
sample size, which hampered thorough statistical analyses of several 
of our observations. Moreover, selection bias cannot be excluded. 
Nevertheless, where previous studies mainly focused on the patients, 
we were able to show here that the microbiota of the donor is a 
major factor in treatment success. This finding is supported by the 
observation of Moayyedi and colleagues38 that successful FMT was 
highly donor-dependent. We demonstrate for the first time that 
higher absolute baseline richness in donors is associated with suc-
cessful FMT. Besides high richness, a successful donor also needs to 
have a transferable dose of biologically important phylotypes. The 
latter is in line with the finding of Rossen and colleagues,39 who 
observed a shift in the microbiota of patients receiving the active 
treatment towards their respective donor.
Among the phylotypes that were transferred, we revealed 
Roseburia and Oscillibacter to be specific for a successful bacterial 
imprint to induce remission in UC. Although these observations 
did not reach significance, it is noteworthy that Oscillibacter abun-
dance has been negatively correlated to CD in earlier studies.47,48 
Roseburia is a butyrate-producing genus and Angelberger and col-
leagues33 also reported colonization of donor-derived Roseburia 
faecis in their patient that had a successful FMT. Moreover, in previ-
ous work an inverse relation between disease activity and the abun-
dance of Roseburia hominis in UC patients was demonstrated.20
Although we observed overlap in phylotypes that were trans-
ferred in both responders and non-responders, a higher number of 
transferred phylotypes was a key point for a transplant to work. 
A successful donor should thus enable sufficient enrichment of the 
microbiota of a patient to induce remission. At week 8, we indeed 
observed a trend of higher bacterial richness in samples of respond-
ers, in line with the accumulating evidence of a correlation between 
microbial richness and overall health.13,49
In conclusion, we observed a difference in efficacy following 
FMT between patients with CD and UC. CRP was an early marker 
of failure of FMT and higher baseline richness in the donor sample 
was crucial for successful bacterial enrichment and to induce remis-
sion. As UC patients tend to have higher baseline microbial richness 
compared with CD patients, this probably further contributes to the 
difference in success between the two IBD phenotypes. Based on our 
data, FMT with donor prescreening could therefore be a potential 
treatment for UC patients refractory to standard medical therapy. 
Gradual enrichment of the faecal microbiota by repeated FMT with 
high-richness donors should be considered to further improve the 
success rate of FMT in IBD.
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